Serine ( DrugBank: Serine )

4 diseases

2. 筋萎縮性側索硬化症

臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03580616 (ClinicalTrials.gov)	October 24, 2018	26/6/2018	Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)	Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa Study	Amyotrophic Lateral Sclerosis (ALS)	Drug: L-Serine	Elijah W. Stommel	Brain Chemistry Labs, Institute for Ethnomedicine	Recruiting	18 Years	N/A	All	50	Phase 2	United States
2	NCT01835782 (ClinicalTrials.gov)	January 2013	27/3/2013	Determining the Safety of L-serine in ALS	Determining the Safety of L-Serine in Subjects With Amyotrophic Lateral Sclerois (ALS) at Varied Doses.	Amyotrophic Lateral Sclerosis (ALS)	Drug: L-Serine	Phoenix Neurological Associates, LTD	Institute for Ethnomedicine	Active, not recruiting	18 Years	85 Years	Both	20	Phase 1/Phase 2	United States

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00215904 (ClinicalTrials.gov)	August 2003	18/9/2005	D-serine Adjuvant Treatment for Parkinson's Disease	D-serine Adjuvant Treatment for Parkinson's Disease	Parkinson's Disease	Drug: D-serine (~2g/day)	Herzog Hospital	NULL	Completed	30 Years	75 Years	Both	13	Phase 4	Israel

臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000001709	2009/02/01	16/02/2009	Multikinase Inhibitor (Tyrosine and Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pulmonary Arterial Hypertension		pulmonary arterial hypertension	administration of sorafenib, which is the multikinase inhibitor (tyrosine and serine/threonine kinase inhibitor)	Medical Education Center, School of Medicine, Keio University	NULL	Pending	20years-old	Not applicable	Male and Female	10	Not selected	Japan

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04795960 (ClinicalTrials.gov)	March 18, 2021	9/3/2021	Microbiome Modification to Enhance Stelara Response in Crohn's Disease	Microbiome Modification to Enhance Stelara Response in Crohn's Disease	Crohn Disease	Dietary Supplement: Low serine diet;Dietary Supplement: High serine diet	University of Michigan	Kenneth Rainin Foundation	Recruiting	18 Years	70 Years	All	10	N/A	United States